



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Ranjana Advani, M.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **April 22, 2022**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On April 22<sup>nd</sup>, the committee will discuss supplemental new drug application (sNDA) 213176/S-002, for Ukoniq (umbralisib) tablets, and biologics license application (BLA) 761207, for ublituximab injection, both submitted by TG Therapeutics, Inc. The proposed indication (use) for these two products is in combination for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition, the committee will also discuss the existing umbralisib indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma under 21 CFR 314.500 (subpart H, accelerated approval regulations).

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
employment	Stanford University, competing entity receives royalties for development of competing product	Dr. Advani is not aware of the royalty amount being provided to Stanford University
contract/grant	Gilead, competing firm	\$400,000 – \$500,000 per year to Stanford University  [REDACTED] (b) (6) per year to Dr. Advani in salary support
contract/grant	Regeneron, competing firm	\$200,000 – \$300,000 per year to Stanford University  [REDACTED] (b) (6) per year to Dr. Advani in salary support

